Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate
Contact your provider promptly for neck mass, persistent hoarseness, or difficulty swallowing, which warrant specialist referral
Ultimately, your weight loss journey is a personal one, and your Shapely team will be by your side to help you achieve your best results Typically, we find that patients of our weight loss program in Santa Ana, California who are taking GLP-1 agonists such as Ozempic and Wegovy will lose 10% of weight by 6 months and 15% within 1 year
Researchers are also studying how sublingual semaglutide might work in different groups of people
Your outofpocket cost will largely depend on your insurance type, your diagnosis, and whether your plan still covers obesity drugs
Malaguarnera, R
